Cardionor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker that reduces the spontaneous pacemaker activity of the cardiac sinus node by selectively inhibiting the If current, resulting in heart rate reduction with no effect on ventricular repolarization and no effects on myocardial contractility.

Each tablet of Cardionor 5mg contains 5 mg Ivadradine.

Each tablet of Cardionor 7.5 mg contains 7.5 mg Ivadradine.

Chronic Heart Failure in Adult Patients:

Cardionor is indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use.

Heart Failure in Pediatric Patients:

Cardionor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate.

Pregnancy& breast-feeding

Based on findings in animals, Cardionor may cause fetal harm when administered to a pregnant woman.

Taking Cardionor is not recommended if you are pregnant (Category D).

Because of the potential risk to breastfed infants from exposure to Cardionor, breastfeeding is not recommended.

Adults

The recommended starting dose of Cardionor is 5 mg twice daily with food. Assess patient after two weeks and adjust dose to achieve a resting heart rate between 50 and 60 beats per minute (bpm) as shown in Table 1. Thereafter, adjust dose as needed based on resting heart rate and tolerability. The maximum dose is 7.5 mg twice daily.

In patients with a history of conduction defects or other patients in whom bradycardia, initiate therapy at 2.5 mg twice daily before increasing the dose based on heart rate.

Table 1. Dose Adjustment for Adults

Pediatric Patients weighing more than 40 kg

The recommended starting dose of Cardionor tablets in pediatric patients weighing more than 40 kg is 2.5 mg twice daily with food. Assess patient at two-week intervals and adjust dose by 2.5 mg to target a heart rate (HR) reduction of at least 20%, based on tolerability. The maximum dose is 7.5 mg twice daily.